PYC Therapeutics has successfully closed its retail entitlement offer, raising approximately $47 million at $1.50 per new share with a 40% take-up rate. New shares are set to begin trading on the ASX from 9 March 2026.
- Retail entitlement offer raised $47 million at $1.50 per share
- 40% take-up rate from eligible retail shareholders
- Approximately 11 million shares to be issued to underwriters
- New shares expected to trade on ASX from 9 March 2026
- Remaining shares may be placed within three months at directors’ discretion
Completion of Retail Entitlement Offer
PYC Therapeutics Limited (ASX:PYC), a clinical-stage biotechnology company focused on RNA therapies for genetic diseases, has completed the retail component of its pro rata accelerated non-renounceable entitlement offer. The retail offer closed on 27 February 2026, successfully raising approximately $47 million at an offer price of $1.50 per new share.
The offer saw eligible retail shareholders apply for around 31 million new shares, representing a 40% take-up rate. Notably, shareholders were able to apply for additional shares up to 100% of their entitlement, and those applications have been fully allotted.
Underwriting and Remaining Shares
Of the approximately 46 million new shares not taken up during the retail offer, about 11 million will be issued to underwriters as per the underwriting agreement with existing large shareholders. These shares are expected to be issued around 10 March 2026.
The company retains the option to place the remaining 35 million shares not subscribed by retail investors or underwriters within three months following the retail offer’s close. Any such placements will be at or above the offer price and at the directors’ discretion, aimed at serving the company’s best interests.
Next Steps and Market Impact
New shares from the retail entitlement offer are scheduled for issue on 6 March 2026 and will commence trading on the ASX on 9 March 2026. These shares will rank equally with existing shares, with holding statements expected to be dispatched by 10 March.
This capital raising strengthens PYC Therapeutics’ financial position as it advances its proprietary RNA drug delivery platform targeting monogenic diseases. The fresh funds are likely to support ongoing clinical development programs and potentially accelerate pipeline progress.
Investors will be watching closely how the remaining shares are allocated and whether further placements might impact share price dynamics in the near term.
Bottom Line?
PYC’s successful raise bolsters its growth runway, but upcoming share placements warrant close investor attention.
Questions in the middle?
- How will the directors allocate the remaining 35 million shares not yet placed?
- What impact will the new share issuance have on PYC’s share price post-trading commencement?
- How will this capital injection accelerate PYC’s clinical development timelines and milestones?